The European supply of vaccines will not be increased by forcing pharmaceutical companies to release their patents, and even if this had been the case, the current vaccine production has progressed to a point where notions of mandatory patent releases will be quite outdated and irrelevant in a few months.
So state two experts on patents and the pharmaceutical industry, with whom MedWatch has spoken.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.